Molecular magnetic resonance imaging of angiogenesis in vivo using polyvalent cyclic RGD-iron oxide microparticle conjugates

Theranostics

Volumn 5, Issue 5, 2015, Pages 515-529

  Melemenidis, Stavros ^a   Jefferson, Andrew ^a   Ruparelia, Neil ^a   Akhtar, Asim M ^a   Xie, Jin ^b   Allen, Danny ^a   Hamilton, Alastair ^a   Larkin, James R ^a   Perez Balderas, Francisco ^a   Smart, Sean C ^a   Muschel, Ruth J ^a   Chen, Xiaoyuan ^b   Sibson, Nicola R ^a   Choudhury, Robin P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Angiogenesis; CRGDyK; DCE; Microparticles; MRI; Tumour

Indexed keywords

ARGINYLALANYLASPARTIC ACID IRON OXIDE NANOPARTICLE; ARGINYLGLYCYLASPARTIC ACID IRON OXIDE NANOPARTICLE; CONTRAST MEDIUM; GADODIAMIDE; N ACETYL S NITROSOPENICILLAMINE; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; FERRIC ION; FERRIC OXIDE; MICROSPHERE; OLIGOPEPTIDE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; COLORECTAL CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DRUG CLEARANCE; DRUG CONJUGATION; FEMALE; HUMAN; HUMAN CELL; IMAGE DISPLAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; C57BL MOUSE; CELL CULTURE; ENDOTHELIUM CELL; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PROCEDURES; RADIOGRAPHY;

ANIMALS; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; FERRIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE, INBRED C57BL; MICROSPHERES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PROTEIN BINDING;

EID: 84930212338     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10319     Document Type: Article

References (56)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992; 3(2): 65-71.
2. Weinstat-Saslow D, Steeg PS. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J. 1994; 8(6): 401-407.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1(1): 27-31.
4. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science. 2006; 312(5777): 1171-1175.
5. Mulder WJ, van der Schaft DW, Hautvast PA, Strijkers GJ, Koning GA, Storm G, et al. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J. 2007; 21(2): 378-383.
6. Horton MA. The alpha v beta 3 integrin "vitronectin receptor". Int J Biochem Cell Biol. 1997; 29(5): 721-725.
7. Drake CJ, Cheresh DA, Little CD. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci. 1995;108 (7): 2655-2661.
8. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000; 52(2): 237-268.
9. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994; 79(7): 1157-1164.
10. Gladson CL. Expression of integrin αvβ3 in small blood vessels of glioblastoma tumors. Journal of Neuropathology & Experimental Neurology. 1996; 55: 1143-1149.
11. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998; 4(5): 623-626.
12. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008; 49 (Suppl 2): 113S-28S.
13. Buck CA, Horwitz AF. Cell surface receptors for extracellular matrix molecules. Annu Rev Cell Biol. 1987; 3: 179-205.
14. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986; 44(4): 517-518.
15. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science. 2002; 296(5565): 151-155.
16. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med. 1998; 25(10): 1383-1389.
17. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001; 61(5): 1781-1785.
18. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med. 2005; 53(3): 621-627.
19. Kiessling F, Morgenstern B, Zhang C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem. 2007; 14(1): 77-91.
20. Mulder WJ, Strijkers GJ, Habets JW, Bleeker EJ, van der Schaft DW, Storm G, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 2005; 19(14): 2008-2010.
21. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia. 2006; 8(3): 214-222.
22. Persigehl T, Matuszewski L, Kessler T, Wall A, Meier N, Ebert W, et al. Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. Invest Radiol. 2007; 42(12): 791-796.
23. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007; 67(4): 1555-1562.
24. Yang Y, Yang Y, Yanasak N, Schumacher A, Hu TC. Temporal and noninvasive monitoring of inflammatory-cell infiltration to myocardial infarction sites using micrometer-sized iron oxide particles. Magn Reson Med. 2010; 63(1): 33-40.
25. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005; 23(11): 1418-1423.
26. Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP. MRI detection of single particles for cellular imaging. Proc Natl Acad Sci U S A. 2004; 101(30): 10901-10906.
27. McAteer MA, Sibson NR, von Zur Muhlen C, Schneider JE, Lowe AS, Warrick N, et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med. 2007; 13(10): 1253-1258.
28. McAteer MA, Mankia K, Ruparelia N, Jefferson A, Nugent HB, Stork LA, et al. A leukocyte-mimetic magnetic resonance imaging contrast agent homes rapidly to activated endothelium and tracks with atherosclerotic lesion macrophage content. Arterioscler Thromb Vasc Biol. 2012; 32(6): 1427-1435.
29. McAteer MA, Schneider JE, Ali ZA, Warrick N, Bursill CA, von zur Muhlen C, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol. 2008; 28(1): 77-83.
30. von Zur Muhlen C, Sibson NR, Peter K, Campbell SJ, Wilainam P, Grau GE, et al. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest. 2008; 118(3): 1198-1207.
31. von zur Muhlen C, von Elverfeldt D, Moeller JA, Choudhury RP, Paul D, Hagemeyer CE, et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008; 118(3): 258-267.
32. Serres S, Anthony DC, Jiang Y, Broom KA, Campbell SJ, Tyler DJ, et al. Systemic inflammatory response reactivates immune-mediated lesions in rat brain. J Neurosci. 2009; 29(15): 4820-4828.
33. Akhtar AM, Schneider JE, Chapman SJ, Jefferson A, Digby JE, Mankia K, et al. In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One. 2010; 5(9): e12800.
34. Hoyte LC, Brooks KJ, Nagel S, Akhtar A, Chen R, Mardiguian S, et al. Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab. 2010; 30(6): 1178-1187.
35. Serres S, Mardiguian S, Campbell SJ, McAteer MA, Akhtar A, Krapitchev A, et al. VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis. FASEB J. 2011; 25(12): 4415-4422.
36. Serres S, Soto MS, Hamilton A, McAteer MA, Carbonell WS, Robson MD, et al. Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci U S A. 2012; 109(17): 6674-6679.
37. Jefferson A, Wijesurendra RS, McAteer MA, Digby JE, Douglas G, Bannister T, et al. Molecular imaging with optical coherence tomography using ligand-conjugated microparticles that detect activated endothelial cells: rational design through target quantification. Atherosclerosis. 2011; 219(2): 579-587.
38. Cai W, Shin DW, Chen K, Gheysens O, Cao Q, Wang SX, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006; 6(4): 669-676.
39. Lee PC, Kibbe MR, Schuchert MJ, Stolz DB, Watkins SC, Griffith BP, et al. Nitric oxide induces angiogenesis and upregulates alpha(v)beta(3) integrin expression on endothelial cells. Microvasc Res. 2000; 60(3): 269-280.
40. Cassidy PJ, Schneider JE, Grieve SM, Lygate C, Neubauer S, Clarke K. Assessment of motion gating strategies for mouse magnetic resonance at high magnetic fields. J Magn Reson Imaging. 2004; 19(2): 229-237.
41. Yarnykh VL. Actual flip-angle imaging in the pulsed steady state: a method for rapid three-dimensional mapping of the transmitted radiofrequency field. Magn Reson Med. 2007; 57(1): 192-200.
42. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006; 31(3): 1116-1128.
43. Yankeelov TE, Luci JJ, Lepage M, Li R, Debusk L, Lin PC, et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging. 2005; 23(4): 519-529.
44. Yankeelov TE, DeBusk LM, Billheimer DD, Luci JJ, Lin PC, Price RR, et al. Repeatability of a reference region model for analysis of murine DCE-MRI data at 7T. J Magn Reson Imaging. 2006; 24(5): 1140-1147.
45. Yankeelov TE, Luci JJ, DeBusk LM, Lin PC, Gore JC. Incorporating the effects of transcytolemmal water exchange in a reference region model for DCE-MRI analysis: theory, simulations, and experimental results. Magn Reson Med. 2008; 59(2): 326-335.
46. Fonnum G, Johansson C, Molteberg A, Mørup S, Aksnes E. Characterisation of Dynabeads® by magnetization measurements and Mössbauer spectroscopy. J Magn Magn Mater. 2005; 293(1): 41-47.
47. Xie J, Chen K, Lee HY, Xu C, Hsu AR, Peng S, et al. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc. 2008; 130(24): 7542-7543.
48. Cai W, Chen X. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc. 2008; 3(1): 89-96.
49. Huo T, Du X, Zhang S, Liu X, Li X. Gd-EDDA/HYNIC-RGD as an MR molecular probe imaging integrin alphanubeta3 receptor-expressed tumor-MR molecular imaging of angiogenesis. Eur J Radiol. 2010; 73(2): 420-427.
50. Kiessling F, Farhan N, Lichy MP, Vosseler S, Heilmann M, Krix M, et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia. 2004; 6(3): 213-223.
51. Park JA, Lee JJ, Jung JC, Yu DY, Oh C, Ha S, et al. Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent. Chembiochem. 2008; 9(17): 2811-2813.
52. Giraudeau C, Geffroy F, Meriaux S, Boumezbeur F, Robert P, Port M, et al. 19F molecular MR imaging for detection of brain tumor angiogenesis: in vivo validation using targeted PFOB nanoparticles. Angiogenesis. 2013; 16(1): 171-179.
53. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003; 63(18): 5838-5843.
54. Schmieder AH, Caruthers SD, Zhang H, Williams TA, Robertson JD, Wickline SA, et al. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 2008; 22(12): 4179-4189.
55. Jiang T, Zhang C, Zheng X, Xu X, Xie X, Liu H, et al. Noninvasively characterizing the different alphavbeta3 expression patterns in lung cancers with RGD-USPIO using a clinical 3.0T MR scanner. Int J Nanomedicine. 2009; 4: 241-249.
56. Perez-Balderas F. Multimeric iron oxide micro particles: Novel high sensitivity and biodegradable mri contrast agents. Intl Soc Mag Reson Med. 2010.